Tuesday, 5 May 2026
  
Login

Australia's most trusted
source of pharma news

Tuesday, 05 May 2026
News

Finally... CAR T funded after five years

Posted 5 May 2026 PM

Johnson & Johnson Innovative Medicine’s Carvyti has become the fourth CAR T-cell therapy to be reimbursed in Australia – and the first for multiple myeloma – marking almost 1,200 working days since it was first submitted to the TGA.

Under a landmark funding arrangement between the Federal Government, Victorian Government and J&J, Carvykti will be provided at no cost to eligible Australians with multiple myeloma who have exhausted other available treatments and meet certain criteria.

To see the whole article, please login

Popular

Who's made a move to new digs?
Who's won an MA Board seat?
Aussie pharma on the nose
Lilly GM confirms drug launch
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home